Colombote: The Lung06 phase III trial has reached the primary endpoint, and sac-TMT combination therapy has verified the potential of first-line NSCLC backbone, and is optimistic (
A Goldman Sachs report shows that the Phase III trial of Colombote (6990.HK) OptiTROP-Lung06 achieved the primary endpoint.
A Goldman Sachs report shows that the Phase III trial of Colombote (6990.HK) OptiTROP-Lung06 achieved the primary endpoint. sac-TMT combined with pembrolizumab was significantly better in PFS than standard therapy, with a controllable safety profile and a positive OS trend, further validating the potential of sac-TMT as a backbone therapy for first-line non-small cell lung cancer. This result also provides direct evidence of superiority for the global Phase III trial of the KEYNOTE-189 population, reducing the risk of related clinical advancement. The market already has some awareness of Colombote's TROP2-ADC, but the positive data from Lung06 further confirms its potential as a first-line therapy, helping to increase valuations. One-sentence conclusion: The success of Colombote's Lung06 trial has strengthened its positioning of sac-TMT as a cornerstone therapy for first-line NSCLC. The risks of global phase III trials have been reduced, and the current valuation is attractive. Positive/negative: Positive for Kelun Botai (6990.HK). The market has some expectations for the success of the Lung06 trial, but positive data will further enhance market confidence in the success of the global Phase III trial and commercialization prospects, and there is room for upward valuation adjustments. Catalysts: 1) publication of detailed data from Lung06; 2) patient enrollment and interim data from the global Phase III trial; 3) progress in regulatory approval of sac-TMT.